American histoplasmosis in developing countries with a special focus on patients with HIV: Diagnosis, treatment, and prognosis

Current Opinion in Infectious Diseases

Volumn 19, Issue 5, 2006, Pages 443-449

  Couppié, Pierre ^a,b,c   Aznar, Christine ^b,c   Carme, Bernard ^b,c   Nacher, Mathieu ^b,c  

^a Service de Dermatologie   (French Guiana)

^b CENTRE HOSPITALIER DE CAYENNE   (French Guiana)

^c UNIVERSITÉ DES ANTILLES ET DE LA GUYANE   (France)

Author keywords

AIDS; Cutaneous lesions; Histoplasmosis; Tuberculosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; CASPOFUNGIN; COTRIMOXAZOLE; FLUCONAZOLE; GENERIC DRUG; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; RIFABUTIN; RIFAMPICIN; VORICONAZOLE; ZIDOVUDINE;

CLINICAL FEATURE; DELAYED DIAGNOSIS; DEVELOPING COUNTRY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG COST; DRUG HALF LIFE; FUNGAL EXAMINATION; FUNGAL VIRULENCE; FUNGUS ISOLATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NORTH AMERICA; PHYSICAL EXAMINATION; PROGNOSIS; REVIEW; SOUTH AMERICA; TREATMENT PLANNING; TUBERCULOSIS;

HISTOPLASMA; HISTOPLASMOSIS; HIV INFECTIONS; HUMANS; NORTH AMERICA; PROGNOSIS; SOUTH AMERICA;

EID: 33748347475     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000244049.15888.b9     Document Type: Review

References (54)

1. Couppie P, Clyti E, Nacher M, et al. Acquired immunodeficiency syndrome-related oral and/or cutaneous histoplasmosis: a descriptive and comparative study of 21 cases in French Guiana. Int J Dermatol 2002; 41:571-576.
2. Hernandez SL, Lopez De Blanc SA, Sambuelli RH, et al. Oral histoplasmosis associated with HIV infection: a comparative study. J Oral Pathol Med 2004; 33:445-450.
3. Kahi CJ, Wheat LJ, Allen SD, Sarosi GA. Gastrointestinal histoplasmosis. Am J Gastroenterol 2005; 100:220-231. Review of the management of gastrointestinal histoplasmosis, which may be misdiagnosed as inflammatory bowel disease.
4. Assi M, McKinsey DS, Driks MR et al. Gastrointestinal histoplasmosis in the acquired immunodeficiency syndrome: report of 18 cases and literature review. Diagn Microbiol Infect Dis. 2006. March 16 [Epub ahead of print]. The largest series in the literature concerning AIDS-related digestive histoplasmosis.
5. Butt AA, Michaels S, Greer D, et al. Serum LDH level as a clue to the diagnosis of histoplasmosis. AIDS Read 2002; 12:317-321.
6. Neubauer MA, Bodensteiner DC. Disseminated histoplasmosis in patients with AIDS. South Med J 1992; 85:1166-1170.
7. Akpek G, Lee SM, Gagnon DR, et al. Bone marrow aspiration, biopsy, and culture in the evaluation of HIV-infected patients for invasive mycobacteria and histoplasma infections. Am J Hematol 2001; 67:100-106.
8. Sathapatayavongs B, Batteiger BE, Wheat J, et al. Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine (Baltimore) 1983; 62:263-270.
9. Unis G, da Silva VB, Severo LC. Disseminated histoplasmosis and AIDS: the role of culture medium for the bronchoscopic clinical specimens. Rev Soc Bras Med Trop 2004; 37:234-237.
10. Santiago AR, Hernandez B, Rodriguez M, Romero H. A comparative study of blood culture conventional method vs a modified lysis/centrifugation technique for the diagnosis of fungemias. Rev Iberoam Micol 2004; 21:198-201.
11. Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990; 69:361-374.
12. Leimann BC, Pizzini CV, Muniz MM, et al. Histoplasmosis in a Brazilian center: clinical forms and laboratory tests. Rev Iberoam Micol 2005; 22:141-146. This retrospective study conducted in Rio de Janeiro compares HIV-positive and HIV-negative histoplasmosis with standard values concerning the positivity of the different diagnostic methods used.
13. Wheat LJ, Musial CE, Jenny-Avital E. Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis 2005; 40:844-852. Opinion on management of central nervous system histoplasmosis in the context of absence of prospective studies in the medical literature.
14. Guimaraes AJ, Pizzini CV, De Matos Guedes HL, et al. ELISA for early diagnosis of histoplasmosis. J Med Microbiol 2004; 53:509-514.
15. Wheat LJ, Garringer T, Brizendine E, Connolly P. Diagnosis of histoplasmosis by antigen detection based upon experience at the histoplasmosis reference laboratory. Diagn Microbiol Infect Dis 2002; 43:29-37.
16. Wheat J, Wheat H, Connolly P, et al. Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses. Clin Infect Dis 1997; 24:1169-1171.
17. Wheat LJ, Connolly P, Durkin M, et al. False-positive Histoplasma antigenemia caused by antithymocyte globulin antibodies. Transpl Infect Dis 2004; 6:23-27.
18. Kersulyte D, Woods JP, Keath EJ, et al. Diversity among clinical isolates of Histoplasma capsulatum detected by polymerase chain reaction with arbitrary primers. J Bacteriol 1992; 174:7075-7079.
19. Rickerts V, Bialek R, Tintelnot K, et al. Rapid PCR-based diagnosis of disseminated histoplasmosis in an AIDS patient. Eur J Clin Microbiol Infect Dis 2002; 21:821-823.
20. Bracca A, Tosello ME, Girardini JE, et al. Molecular detection of Histoplasma capsulatum var. capsulatum in human clinical samples. J Clin Microbiol 2003; 41:1753-1755.
21. Martagon-Villamil J, Shrestha N, Sholtis M, et al. Identification of Histoplasma capsulatum from culture extracts by real-time PCR. J Clin Microbiol 2003; 41:1295-1298.
22. Tang YW, Li H, Durkin MM, et al. Urine polymerase chain reaction is not as sensitive as urine antigen for the diagnosis of disseminated histoplasmosis. Diagn Microbiol Infect Dis 2006; 54:283-287. The results were expected but had never been previously demonstrated because although Histoplasma antigen excretion through the urine is common, the presence of Histoplasma in the kidneys is rare.
23. Nacher M, Aznar C, Blanchet D, et al. AIDS-related disseminated histoplasmosis in the greater Caribbean: how frequent is it? AIDS 2006; 20:951-952. The question is raised of a possible underestimation of histoplasmosis in the 'greater Caribbean'.
24. Nacher M, Sarazin F, El Guedj M, et al. Increased incidence of disseminated histoplasmosis following highly active antiretroviral therapy initiation. J Acquir Immune Defic Syndr 2006; 41:468-470. Like mycobacterial infections, histoplasmosis may appear or worsen clinically in the first months following HAART.
25. Mocherla S, Wheat LJ. Treatment of histoplasmosis. Semin Respir Infect 2001; 16:141-148.
26. Centers for Disease Control and Prevention. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2004; 53(No. RR-15):34-35.
27. Wheat LJ. Histoplasmosis in the acquired immunodeficiency syndrome. Curr Top Med Mycol 1996; 7:7-18.
28. Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med 1995; 98:336-342.
29. Wheat LJ, Connolly P, Haddad N, et al. Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrob Agents Chemother 2002; 46:248-250.
30. Wheat LJ, Cloud G, Johnson PC, et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob Agents Chemother 2001; 45:2354-2357.
31. Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137:105-109.
32. Wheat J, MaWhinney S, Hafner R, et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am J Med 1997; 103:223-232.
33. Connolly P, Wheat LJ, Schnizlein-Bick C, et al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob Agents Chemother 2000; 44:2604-2608.
34. Clark B, Foster R, Tunbridge A, Green S. A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole. J Infect 2005; 51:e177-e180.
35. Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994; 18:266.
36. Jaruratanasirikul S, Sriwiriyajan S. Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. Eur J Clin Pharmacol 1998; 54:155-158.
37. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002; 162:985-992.
38. Goldman M, Zackin R, Fichtenbaum CJ, et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis 2004; 38:1485-1489.
39. Negroni R, Helou SH, Lopez-Daneri G, et al. Interruption of antifungal secondary prophylaxis in AIDS-related histoplasmosis. Rev Iberoam Micol 2004; 21:75-78.
40. Wheat LJ, Chetchotisakd P, Williams B, et al. Factors associated with severe manifestations of histoplasmosis in AIDS. Clin Infect Dis 2000; 30:877-881.
41. Hajjeh RA, Pappas PG, Henderson H, et al. Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons. Clin Infect Dis 2001; 32:1215-1220.
42. Couppié P, Sobesky M, Aznar C, et al. Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors. Clin Infect Dis 2004; 38:134-138.
43. de Francesco Daher E, de Sousa Barros FA, da Silva GB Jr, et al. Risk factors for death in acquired immunodeficiency syndrome-associated disseminated histoplasmosis. Am J Trop Med Hyg 2006; 74:600-603. This study on prognostic factors includes the largest number of cases in the literature, but it is retrospective.
44. Butt AA, Michaels S, Kissinger P. The association of serum lactate dehydrogenase level with selected opportunistic infections and HIV progression. Int J Infect Dis 2002; 6:178-181.
45. Corcoran GR, Al-Abdely H, Flanders CD, et al. Markedly elevated serum lactate dehydrogenase levels are a clue to the diagnosis of disseminated histoplasmosis in patients with AIDS. Clin Infect Dis 1997; 24:942-944.
46. Gutierrez ME, Canton A, Sosa N, et al. Disseminated histoplasmosis in patients with AIDS in Panama: a review of 104 cases. Clin Infect Dis 2005; 40:1199-1202. Notes the frequency of histoplasmosis as an opportunistic infection in Panama and the predominant use of amphotericin B as first-line treatment.
47. Tobon AM, Agudelo CA, Rosero DS, et al. Disseminated histoplasmosis: a comparative study between patients with acquired immunodeficiency syndrome and nonhuman immunodeficiency virus-infected individuals. Am J Trop Med Hyg 2005; 73:576-582. Columbian comparative study between disseminated histoplasmosis in HIV-positive and HIV-negative patients followed by a comparison between disseminated histoplasmosis in patients with HIV infection with and without HAART. The sample size is small (30 HIV-positive patients).
48. Karimi K, Wheat LJ, Connolly P, et al. Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil. J Infect Dis 2002; 186:1655-1660.
49. Unis G, Oliveira Fde M, Severo LC. Disseminated histoplasmosis in Rio Grande do Sul. Rev Soc Bras Med Trop 2004; 37:463-468.
50. Négroni R, Taborda A, Robies AM, Archevala A. Itraconazole in the treatment of histoplasmosis associated with AIDS. Mycoses 1992; 35:281-287.
51. Pietrobon D, Negro-Marquinez L, Kilstein J, et al. Disseminated histoplasmosis and AIDS in an Argentine hospital: clinical manifestations, diagnosis and treatment. Enferm Infecc Microbiol Clin 2004; 22:156-159.
52. Durkin MM, Connolly PA, Karimi K, et al. Pathogenic differences between North American and Latin American strains of Histoplasma capsulatum var. capsulatum in experimentally infected mice. J Clin Microbiol 2004; 42:4370-4373.
53. Nightingale SD, Parks JM, Pounders SM, et al. Disseminated histoplasmosis in patients with AIDS. South Med J 1990; 83:624-630.
54. Mootsikapun P, Srikulbutr S. Histoplasmosis and penicilliosis: comparison of clinical features, laboratory findings and outcome. Int J Infect Dis 2006; 10:66-71. Interesting study addressing the differential diagnosis between penicilliosis and American histoplasmosis that may arise in southeast Asia.